SEC Form 4 · accession 0000899243-18-024949
T2 Biosystems, Inc. · TTOO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas J. Lowery
Officer — Chief Scientific Officer
Period of report
Sep 18, 2018
Accepted (ET)
Sep 20, 2018 · 6:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001492674
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 18, 2018 | M | 14,647 | $1.16 | A | 57,873 | D | |
| Common Stock | Sep 18, 2018 | M | 18,588 | $1.31 | A | 76,461 | D | |
| Common Stock | Sep 18, 2018 | M | 29,411 | $1.96 | A | 105,872 | D | |
| Common Stock | Sep 18, 2018 | M | 36,235 | $2.45 | A | 142,107 | D | |
| Common Stock | Sep 18, 2018 | M | 1,361 | $2.25 | A | 143,468 | D | |
| Common StockF2 | Sep 18, 2018 | S | 14,647 | $6.14 | D | 128,821 | D | |
| Common StockF3 | Sep 18, 2018 | S | 85,595 | $6.17 | D | 43,226 | D | |
| Common Stock | Sep 19, 2018 | M | 10,403 | $2.25 | A | 53,629 | D | |
| Common Stock | Sep 19, 2018 | M | 27,499 | $3.22 | A | 81,128 | D | |
| Common StockF4 | Sep 19, 2018 | S | 37,902 | $6.20 | D | 43,226 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $1.16 | Sep 18, 2018 | M | 14,647 | D | Feb 27, 2013 | Feb 27, 2019 | Common Stock | 14,647 | 0 | D |
| Stock Option (Right to Buy) | $1.31 | Sep 18, 2018 | M | 18,588 | D | Feb 5, 2014 | Feb 5, 2020 | Common Stock | 18,588 | 0 | D |
| (Stock Option (Right to Buy) | $1.96 | Sep 18, 2018 | M | 29,411 | D | Apr 15, 2015 | Apr 15, 2021 | Common Stock | 29,411 | 0 | D |
| Stock Option (Right to Buy) | $2.45 | Sep 18, 2018 | M | 36,235 | D | Jan 17, 2016 | Jan 17, 2022 | Common Stock | 36,235 | 0 | D |
| Stock Option (Right to Buy) | $2.25 | Sep 18, 2018 | M | 1,361 | D | Jan 23, 2017 | Jan 23, 2023 | Common Stock | 1,361 | 10,403 | D |
| Stock Option (Right to Buy) | $2.25 | Sep 19, 2018 | M | 10,403 | D | Jan 23, 2017 | Jan 23, 2023 | Common Stock | 10,403 | 0 | D |
| Stock Option (Right to Buy) | $3.22 | Sep 19, 2018 | M | 27,499 | D | Sep 25, 2017 | Sep 25, 2023 | Common Stock | 27,499 | 31,603 | D |
Explanation of responses
- F1The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2018.
- F2The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $6.05 to $6.27. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $6.05 to $6.30. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4The price reported is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $6.05 to $6.30. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.